Ganaxolone vs Staccato Alprazolam

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Ganaxolone

Marketed by Immedica Pharma AB

Approved in Epilepsysmall molecule
Partial signal

NCT01963208 · Phase 3 · completed

The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.

Reported efficacy

Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes); Percentage of Participants With no Progression to Intravenous (IV) Anesthesia for 36 Hours Following Investigational Product (IP) Initiation (Up to 36 hours after IP initiation); Number of Participants With Treatment Emergent Adverse Events (Up to 4 weeks after IP initiation): Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) (mixed)

Result source: NCT04391569

Staccato Alprazolam

Developed by UCB and partners

Phase 3 in Epilepsysmall molecule
Reliable signal

NCT03478982 · Phase 2 · completed

The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.

Next expected readout: March 2027 · NCT05077904 (registry estimate)

Reported efficacy

Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours (2 hours post-dosing on dosing day): 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) (met)

Result source: NCT03478982

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointGanaxoloneStaccato Alprazolam
Seizure frequency, % change-7.5% vs 13.6%−21.1 vs placebowk 4 · n 64NCT05323734
4 other results
  • -61.5% vs -24.0% wk 17 · n 10 · Phase 2 · primary NCT03865732
  • -17.6% vs 2.0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • -12.1% vs 4.6% wk 10 · n 95 · Phase 2 · secondary NCT00465517
  • -35.9% vs -18.7% wk 17 · n 6 · Phase 2 · secondary NCT03865732
—Trial running · NCT05076617
50% responder rate18.8% vs 12.3%+6.5 vs placebowk 16 · n 64NCT05323734
3 other results
  • 23.5% vs 14.3% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 25.5% vs 12.2% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 50% vs 36.4% wk 17 · n 10 · Phase 2 · secondary NCT03865732
—Trial running · NCT05076617
Seizure freedom0% vs 2.2%−2.2 vs placebowk 10 · n 95NCT00465517
2 other results
  • 1% vs 0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 16.8% vs 8.3% wk 2 · n 95 · Phase 2 · secondary NCT00465517
—Trial running · NCT05076617

Seizure frequency, % change

Ganaxolone
-7.5% vs 13.6%−21.1 vs placebowk 4 · n 64NCT05323734
4 other results
  • -61.5% vs -24.0% wk 17 · n 10 · Phase 2 · primary NCT03865732
  • -17.6% vs 2.0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • -12.1% vs 4.6% wk 10 · n 95 · Phase 2 · secondary NCT00465517
  • -35.9% vs -18.7% wk 17 · n 6 · Phase 2 · secondary NCT03865732
Staccato Alprazolam
—Trial running · NCT05076617

50% responder rate

Ganaxolone
18.8% vs 12.3%+6.5 vs placebowk 16 · n 64NCT05323734
3 other results
  • 23.5% vs 14.3% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 25.5% vs 12.2% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 50% vs 36.4% wk 17 · n 10 · Phase 2 · secondary NCT03865732
Staccato Alprazolam
—Trial running · NCT05076617

Seizure freedom

Ganaxolone
0% vs 2.2%−2.2 vs placebowk 10 · n 95NCT00465517
2 other results
  • 1% vs 0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 16.8% vs 8.3% wk 2 · n 95 · Phase 2 · secondary NCT00465517
Staccato Alprazolam
—Trial running · NCT05076617
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ganaxolone: 4 of 4 rows · Staccato Alprazolam: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGanaxoloneStaccato Alprazolam
Dropout rate
4.2%Double Blind: Cohort 1 - Ganaxolona
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
24.6%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
41.2%
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
14.1%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
12.5%High
NCT03350035 · Phase 2 · registry result, not featured evidence
40%Low
NCT03350035 · Phase 2 · registry result, not featured evidence
0%Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
42.9%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
100%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
50%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
45.5%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
95.1%
NCT00512317 · Phase 2 · registry result, not featured evidence
36.4%
NCT01002820 · Phase 2 · registry result, not featured evidence
12.2%
NCT00465517 · Phase 2 · registry result, not featured evidence
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
0%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Discontinued due to AEs
4.2%Double Blind: Cohort 1 - Ganaxolona
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
16.8%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
7.8%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
—High
NCT03350035 · Phase 2 · registry result, not featured evidence
—Low
NCT03350035 · Phase 2 · registry result, not featured evidence
—Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
0%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
50%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
10%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
18.2%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
10.6%
NCT00512317 · Phase 2 · registry result, not featured evidence
9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
7.1%
NCT00465517 · Phase 2 · registry result, not featured evidence
—2.0 mgb
NCT03478982 · Phase 2
show 2 more results
—1.0 mg
NCT03478982 · Phase 2
—1.0 mg
NCT03478982 · Phase 2
Serious AEs
0%Double Blind: Cohort 1 - Ganaxolona
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
5%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
7.6%Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
6.9%Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
37.3%
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
7.8%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
25%High
NCT03350035 · Phase 2 · registry result, not featured evidence
40%Low
NCT03350035 · Phase 2 · registry result, not featured evidence
50%Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
14.3%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
50%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
20%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
27.3%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
12.2%
NCT00512317 · Phase 2 · registry result, not featured evidence
9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
5.1%
NCT00465517 · Phase 2 · registry result, not featured evidence
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
2.6%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Most frequent reported AEs
a
ataxia 12.5% (placebo 0%)
sedation 12.5% (placebo 0%)
somnolence 12.5% (placebo 9.5%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
somnolence 22.3% (placebo 9.5%)
dizziness 19% (placebo 0%)
fatigue 11.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
somnolence 7.6% (placebo 9.5%)
fatigue 5.7% (placebo 0%)
headache 5.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
somnolence 16.8% (placebo 9.5%)
dizziness 15.6% (placebo 0%)
fatigue 8.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
hypotension 23.5% (placebo 16.3%)
urinary tract infection 19.6% (placebo 8.2%)
hypothermia 9.8% (placebo 4.1%)
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
somnolence 28.1% (placebo 16.9%)
pyrexia 15.6% (placebo 16.9%)
fatigue 14.1% (placebo 9.2%)
NCT05323734 · Phase 3 · registry result, not featured evidence
somnolence 40% (placebo 27.3%)
aggression 20% (placebo 9.1%)
agitation 20% (placebo 0%)
NCT03865732 · Phase 2 · registry result, not featured evidence
High
somnolence 37.5%
hypercaprnia 25%
hypocalcaemia 25%
NCT03350035 · Phase 2 · registry result, not featured evidence
Low
hypotension 40%
haematuria 20%
pain 20%
NCT03350035 · Phase 2 · registry result, not featured evidence
Medium
hypokalaemia 25%
pain 25%
pneumonia 25%
NCT03350035 · Phase 2 · registry result, not featured evidence
pyrexia 71.4%
upper respiratory tract infection 42.9%
vomiting 42.9%
NCT02358538 · Phase 2 · registry result, not featured evidence
dizziness 50%
sinusitis 50%
somnolence 50%
NCT02358538 · Phase 2 · registry result, not featured evidence
fungal infection 20%
hypersomnia 20%
seizure 20%
NCT02358538 · Phase 2 · registry result, not featured evidence
pyrexia 63.6%
somnolence 54.5%
fatigue 36.4%
NCT02358538 · Phase 2 · registry result, not featured evidence
headache 21.1%
convulsion 16.3%
fatigue 16.3%
NCT00512317 · Phase 2 · registry result, not featured evidence
headache 18.2%
irritability 18.2%
aortic aneurysm 9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
dizziness 16.3% (placebo 8.2%)
fatigue 16.3% (placebo 8.2%)
somnolence 13.3% (placebo 2%)
NCT00465517 · Phase 2 · registry result, not featured evidence
2.0 mgb
cough 18.4% (placebo 0%)
dysgeusia 10.5% (placebo 2.5%)
somnolence 10.5% (placebo 2.5%)
NCT03478982 · Phase 2
show 2 more results
1.0 mg
somnolence 18.4% (placebo 2.5%)
dysgeusia 15.8% (placebo 2.5%)
cough 10.5% (placebo 0%)
NCT03478982 · Phase 2
1.0 mg
cough 12.5% (placebo 0%)
dysmenorrhoea 12.5% (placebo 0%)
gastroenteritis viral 12.5% (placebo 0%)
NCT03478982 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for 12 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ganaxolone

Seizure 50 28.1% (n=178) vs 22.7% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to % from 50 Participants as posted
Seizure Free 0.05 vs 0.03 placebo months @ 14wk
absolute change · months
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to months from 1.47 days as posted
show 1 more result
0.05 vs 0.04 placebo months @ 14wk*
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to months from 1.63 days as posted
Seizure Frequency -1.46 vs -0.33 placebo per 28 day @ 14wk
absolute change · per 28 day
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 1 more result
-1.67 vs -0.64 placebo per 28 day @ 14wk
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Seizure-free 1.12% (n=178) vs 0% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
at Least One Seizure Free Period 17.98% (n=178) vs 18.02% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Time Spent Seizure-free 24% (n=178) vs 17.58% (n=172) placebo @ 14wk
absolute value · percentage points
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
SE Cessation 30 Min 79.59% (n=49) vs 12.77% (n=47) placebo @ 0.003wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
SE no Progression to IV Anesthesia 36 h 63.27% (n=49) vs 51.06% (n=47) placebo @ 0.2143wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
SE no Progression to IV Anesthesia 72h 51.02% (n=49) vs 46.81% (n=47) placebo @ 0.4286wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Time to SE Cessation 0.07 vs 2.85 placebo hours
absolute value · hours
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Treatment Escalation 24 h 55.1% (n=49) vs 80.85% (n=47) placebo @ 0.1429wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Time to Treatment Escalation 5.42 vs 2.32 placebo hours
absolute value · hours
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3

+ 41 further endpoints in the CSV export.

Staccato Alprazolam

Seizure Cessation 2min no Recurrence 2 h 65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
62.5% (n=8) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Rescue Medication Use 7.9% (n=38) vs 7.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
0% (n=8) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
15.8% (n=38) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Secondary Generalization 0% (n=38) vs 0% (n=40) placebo @ 0.14wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
12.5% (n=8) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2
0% (n=38) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ganaxolone's landscape · Staccato Alprazolam's landscape